Avid Bioservices Inc (CDMO)

[entdoc]

hopefully the statistical signicance of reason will trump in these trials. great discussions lately. I agree with the poster who suggested that management consider a PR of clarification in re. to the PII MOS questions broadcast here. It would be a wonderful way to focus public and stockholder attention on the critical analysis about to take place. The consensus on "the street" (doctor offices in this case) is that MABs have not lived up to their promise. Avastin faults and Erbitux failures in the solid cancer arena is a reality alluded to on this board in numerous posts, and that reality is obviously at least one reason why the world is not looking to MABs for a cure. The emergent strategy of cancer containment, and cancer as a chronic disease, is gradually supplanting the quest for a cure. This is everywhere apparent as we move further into the genetics of the disease, and an eventual genetic approach to the problem. My take on Bavitux is that it has unmasked a vast new area of inquiry into immunological mechanisms of cancer, and that it will be a part of cancer treatment in the near future. all[of course]IMO